FELINE INFECTIOUS PERITONITIS VACCINE
FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range of FIPVs. In addition, the N proteins are very safe because they do not comprise epitopes that enhance infection. Furthermore, preventive effects can be accomplished against type I viruses, which actually cause 70% or more of FIP.
1 . A vaccine for prophylactic treatment against feline infectious peritonitis virus (FIPV) infection, which comprises:
a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, and one or more adjuvants;
b) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, in which one to 15 amino acids are substituted, deleted, added, and/or inserted, and one or more adjuvants;
c) a polypeptide comprising an amino acid sequence with 95% or more homology to the amino acid sequence of SEQ ID NO: 2, and one or more adjuvants; or
d) one or more polypeptides, each of which comprises different continuous 15 or more amino acid residues of the amino acid sequence of SEQ ID NO:2, and one or more adjuvants.
2 . (canceled)
3 . The vaccine of claim 1 , wherein the the vaccine comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, and one or more adjuvants.
4 . (canceled)
5 . A method for conferring cellular immunity against feline infectious peritonitis virus (FIPV), which comprises administering the vaccine of claim 1 to a cat at least once.
6 - 8 . (canceled)
9 . The vaccine of claim 1 , wherein the vaccine comprises:
(i) one or more polypeptides, each of which comprises different continuous 15 or more amino acid residues of the amino acid sequence of SEQ ID NO:2; and
(ii) one or more adjuvants.
10 . The vaccine of claim 1 , wherein the vaccine comprises:
(i) one or more polypeptides, each of which comprises different continuous 20 or more amino acid residues of the amino acid sequence of SEQ ID NO:2; and
(ii) one or more adjuvants.
11 . The vaccine of any one of claims 1 , 3 , 9 , and 10 , wherein the one or more polypeptides are in a liposome.
12 . The method of claim 5 , wherein the vaccine comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, and one or more adjuvants.
13 . The method of claim 5 , wherein the vaccine comprises:
(i) one or more polypeptides, each of which comprises different continuous 15 or more amino acid residues of the amino acid sequence of SEQ ID NO:2; and
(ii) one or more adjuvants.
14 . The method of claim 5 , wherein the vaccine comprises:
(i) one or more polypeptides, each of which comprises different continuous 20 or more amino acid residues of the amino acid sequence of SEQ ID NO:2; and
(ii) one or more adjuvants.
15 . The method of any one of claims 5 and 12 - 14 , wherein the one or more polypeptides are in a liposome.